Structural and functional characterization of ubiquitin variant inhibitors for the JAMM-family deubiquitinases STAMBP and STAMBPL1

Received for publication, May 10, 2021, and in revised form, August 9, 2021. Published, Papers in Press, August 21, 2021, https://doi.org/10.1016/j.jbc.2021.101107

Yusong Guo1,2,‡, Qi Liu3,4,†, Evan Mallette1, Cody Caba©, Feng Hou1, Julia Fux4, Gabriel LaPlante6, Aiping Dong1, Qi Zhang1, Hui Zheng©, Yufeng Tong2,4,‡, and Wei Zhang2,6,‡

From the 1Fisheries College, Guangdong Ocean University, Guangdong, China; 2Structural Genomics Consortium, University of Toronto, Toronto, Canada; 3Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, Guelph, Canada; 4Department of Chemistry and Biochemistry, University of Windsor, Windsor, Canada; 5Jiangsu Key Laboratory of Infection and Immunity, International Institute of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China; 6CIFAR Azrieli Global Scholars Program, Canadian Institute for Advanced Research, Toronto, Canada

Edited by George DeMartino

Ubiquitination is a crucial posttranslational protein modification involved in a myriad of biological pathways. This modification is reversed by deubiquitinases (DUBs) that deconjugate the single ubiquitin (Ub) moiety or poly-Ub chains from substrates. In the past decade, tremendous efforts have been focused on targeting DUBs for drug discovery. However, most chemical compounds with inhibitory activity for DUBs suffer from mild potency and low selectivity. To overcome these obstacles, we developed a phage display-based protein engineering strategy for generating Ub variant (UbV) inhibitors, which was previously successfully applied to the Ub-specific protease (USP) family of cysteine proteases. In this work, we leveraged the UbV platform to selectively target STAMBP, a member of the JAB1/MPN/MOV34 (JAMM) metalloprotease family of DUB enzymes. We identified two UbVs (UbVSP1 and UbVSP3) that bind to STAMBP with high affinity but differ in their selectivity for the closely related paralog STAMBPL1. We determined the STAMBPL1-UbVSP1 complex structure by X-ray crystallography, revealing hotspots of the JAMM-UbV interaction. Finally, we show that UbVSP1 and UbVSP3 are potent inhibitors of STAMBP isopeptidase activity, far exceeding the reported small-molecule inhibitor BC-1471. This work demonstrates that UbV technology is suitable to develop molecules as tools to target metalloproteases, which can be used to further understand the cellular function of JAMM family DUBs.

Ubiquitin (Ub) is a small, highly conserved protein that plays a central role in the Ub-proteasome system (UPS) to tightly regulate numerous biological processes, including immune responses (1), DNA repair (2), and the cell cycle (3). During ubiquitination, the C-terminal carboxyl group of Ub is covalently attached to a substrate protein at the lysine ε-amine or the N-terminal primary amine through an isopeptide or an α-peptide bond, respectively. The conjugated Ub itself can be further ubiquitinated at its N-terminus or one of seven lysine residues, forming a poly-Ub chain (4). The ubiquitination process is catalyzed by a three-enzyme cascade comprised of E1 activating enzymes, E2 conjugating enzymes, and E3 Ub ligases. Different linkages of poly-Ub chains serve distinct purposes. For example, the most abundant K48-linked poly-Ub chains target substrate proteins to proteasomal degradation (4), whereas K63-linked poly-Ub chains are mostly nondegradative and involved in modulating cellular signal transduction (5).

The antagonists of ubiquitination are the deubiquitinase (DUB) enzymes that deconjugate Ub from modified protein substrates. The human genome encodes approximately 100 DUBs, dysregulation of which results in a variety of diseases (6). DUBs are categorized into seven families based on structural folds: ubiquitin-specific proteases (USPs), JAB1/MPN/MOV34 metalloenzymes (JAMMs), ovarian tumor proteases (OTUs), ubiquitin C-terminal hydrolases (UCHs), Machado-Josephin domain-containing proteases (MJDs), motif interacting with ubiquitin-containing novel DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10). One of the challenges in developing chemical probe quality (11) DUB family (MINDYs) (7, 8), and newly discovered zinc finger containing ubiquitin peptidase (ZUP) (9). DUBs have emerged as attractive targets for pharmacological intervention in various human diseases, particularly cancers (6). However, most small-molecule DUB inhibitors developed have suffered from mild potency and poor selectivity (10).
develop potent and specific inhibitors for the JAMM-family DUBs.

While the other six families of human DUBs are cysteine proteases, the JAMM family is unique in that they are metalloproteases. The JAMM domain (17) contains a catalytic zinc ion coordinated by two histidines, one aspartate/glutamate, and one water molecule that is hydrogen-bonded to an adjacent glutamate (18). The JAMM family comprises a total of 14 DUBs, seven of which are predicted to be catalytically inactive (pseudo-DUBs) because of substitutions of essential Zn$^{2+}$-coordinating residues (19). Among the seven other JAMM members, STAM-binding protein (STAMBP, also known as AMSH), STAMBP-like 1 (STAMBPL1, also known as AMSH-LP), and MYSM1 (20) can function as isopeptidases independently, whereas BRCA1/BRCA2 containing complex subunit 36 (BRCC36), proteasome 26S subunit, non-ATPase 14 (PSMD14, also known as RPN11), and COP9 signalosome subunit 5 (CSN5) act in macromolecular assemblies (21), and finally, the DUB activity and function of MPND are poorly understood (22).

All known broad-spectrum JAMM-family inhibitors are chelating agents (e.g., 1,10-phenanthroline and thiolutin), which have a high affinity for divalent metal ions and chelate the active site Zn$^{2+}$ ion (23, 24). Notably, a potent and moderately specific RPN11 inhibitor capzimin was developed from a chelating agent-like small molecule through medicinal chemistry optimization (25). CSN5i-3 is an orally available inhibitor discovered by Novartis targeting CSN5’s deddylation activity, and it presents high selectivity for CSN5 versus a panel of other metalloproteinases (26). For this work, we chose STAMBP as the representative JAMM DUB for targeted inhibition.

STAMBP consists of three distinct regions, including an N-terminal microtubule interacting and trafficking (MIT) domain, a central SH3-binding motif (SBM), and a C-terminal catalytic JAMM domain (18). STAMBP plays an essential role in endocytosis and endosomal-lysosomal sorting of cell-surface receptors by deubiquitinating and rescuing ubiquitinated cargo proteins from lysosomal degradation. The MIT and SBM domains mediate critical protein–protein interactions (17) to recruit STAMBP to the endosomal sorting complexes required for transport (ESCRT), which regulate the multivesicular body (MVB) biogenesis of ubiquitinated cell complexes required for transport (ESCRT), which regulate the catalytic JAMM domain in complex with K63-linked poly-Ub chains involves the catalytic groove and two insertions that are conserved in STAMBP subfamily JAMMs: ins-1 (aa 314–339) and ins-2 (aa 393–415) (32). The distal Ub interacts with ins-1 and the catalytic groove, and the proximal Ub interacts with ins-2 and the catalytic site. Recently, Bednash et al. used in silico molecular modeling and virtual screening and discovered a compound, BC-1471, which inhibits STAMBP and decreases protein level of its inflammasome substrate NALP7. However, the in vitro DUB assay showed that BC-1471 could not fully inhibit STAMBP activity even at 100 μM and no cocystal structure was provided to support the mechanism of action (33).

In this work, we conducted phage-display selections and identified Ub variant (UbV) inhibitors for STAMBP with high binding affinity. We solved the crystal structure of STAMBPL1 in complex with one of two UbVs and identified the hotspots responsible for tight binding. In addition, in vitro functional characterization confirmed specific and potent inhibition of STAMBP by UbVs. Importantly, the UbVs exhibited an inhibitory effect superior to BC-1471.

Results

Identification of UbV binders for STAMBP

To develop potent and specific inhibitors for STAMBP, we decided to employ a structure-based combinatorial Ub engineering strategy to inhibit the Ub-STAMBP protein–protein interaction (34) selectively. Large hydrophobic surfaces on Ub (~2000 Å$^2$) mediate interaction with DUBs, including the Ile36 patch (Ile36, Leu71, and Leu73), the Ile44 patch (Leu8, Ile44, His68, and Val70), and the Phe4 patch (Gln2, Phe4, Thr14) (35). Ub binds to DUBs with low affinity but high specificity, and thus mutations can be introduced to improve binding affinity without compromising the specificity. Indeed, UbVs for USP-family (34, 36) and OTU-family DUBs (34) can block the binding of substrate Ub to inhibit DUB activity.

We conducted five rounds of selections from an M13 bacteriophage pool representing the UbV library—Library 2 described previously (34)—for phage clones that bind to the biotinylated human full-length STAMBP protein (residues 1–424) (Fig. 1A). A total of 96 clones (48 from Round 4 and 48 from Round 5) were tested for binding activity to STAMBP by phage ELISA. Among them, 53 clones that displayed specific binding with STAMBP were subjected to DNA sequencing, which returned 14 unique UbV sequences (Fig. S1). We then selected the three most potent UbVs (denoted UbV$^{SP1}$, UbV$^{SP2}$, and UbV$^{SP3}$, where “SP” stands for STAMBP) for follow-up characterization (sequences shown in Fig. 1B). Finally, the binding specificity of these UbVs against a panel of seven human DUBs of different families was assessed by phage ELISA (Fig. 1C). All three UbVs were confirmed to bind both the full-length and the JAMM domain of STAMBP (STAMBP$^{JAMM}$), suggesting that the binding was mediated by the JAMM domain. In addition,
UbVSP.1 exhibited cross-reactivity with STAMBPL1, while the other two variants showed significant preferential binding to STAMBP over STAMBPL1. Importantly, all three UbVs showed no binding to two USP-family DUBs (USP7 and USP14), a JAMM-family DUB complex BRISC, or an OTU-family DUB OTUD1.

 Structural characterization of STAMBPL1 in complex with UbVSP.1

We then conducted crystallization trials for STAMBPJAMM or STAMBPL1JAMM in complex with the UbVs. Diffraction-quality crystals could only be obtained for STAMBPL1JAMM in complex with the dual-specific UbVSP.1 despite a sequence identity of 68% between the two catalytic domains (Fig. 2A). We solved the crystal structure of the UbVSP.1/STAMBPJAMM complex at 2.0 Å resolution (PDB:7L97, Fig. 2B and Table 1) in space group C2. The previous STAMBL1JAMM/K63-diUb cocrystal structure (32) revealed that the distal Ub has more extensive contact with the STAMBL1 catalytic domain than the proximal Ub. Not surprisingly, UbVSP.1 occupies the distal Ub position in the structure. A total of 11 mutated residues differentiate UbVSP.1 from Ub.wt (Fig. 1B). The last two C-terminal residues (Ala77 and Ser78) of UbVSP.1 were not observed in the electron density map and were not modeled. Based on the crystal structure, it is evident that seven of the mutated residues (sites 2, 6, 12, 47, 63, 64, and 68) are distant from STAMBL1 and unlikely to contribute to the tight binding observed. (Fig. 2B) The primary interaction interface was observed in the C-terminal tail of UbVSP.1, which includes three mutations, L73H, G75H, and G76S (Fig. 2B). PISA analysis (37) of the interface of the complex structure reveals that the UbV has a buried surface area (BSA) of 1239 Å². In contrast, the seven tail residues of the UbV (residues 70–76) contribute almost half of the BSA with 556 Å².

The overall structure and mode of UbVSP.1 binding are similar to that of the distal Ub observed in the K63-diUb cocrystal structure. The RMSD of the backbone Cα atoms of STAMBP1 in the two structures is only 0.29 Å over 146 residues, whereas the RMSD of UbVSP.1 compared with the distal Ub is 0.34 Å over 66 residues. Superposition of the complex structures in their entirety presents an overall RMSD of 0.56 Å over 212 residues, larger than the RMSDs of the individual molecules, suggesting a relative conformational movement. The conformational changes are most evident for
Figure 2. Crystal structure of the STAMBPL1-UbVSP.1 complex. A, domain architecture of STAMBP and STAMBPL1. The sequences corresponding to the SBM (SH3-binding motif) of STAMBP are indicated. The percentages are sequence identities of the corresponding regions. B, overview of the complex structure. UbVSP.1 is shown in pink with variant residues shown as sticks and labeled. STAMBPL1 is shown in green, the two insertions (ins-1 and ins-2) in teal, and the two zinc ions are shown as orange spheres. C, conformational difference of the STAMBL1 catalytic domain in complex with UbVSP.1 versus with K63-diUb (PDB:2ZNV, diUb omitted for clarity) in backbone sausage view. The radius of the sausage is normalized to the per residue $C_\alpha$ RMSD (in Å) between the minimum and maximum values. D, similar to panel (C), a sausage representation was applied to UbVSP.1 according to per residue $C_\alpha$ RMSD compared with the distal Ub of the STAMBPL1/K63-diUb complex structure, when the STAMBPL1 structures are superimposed. E, a comparison of the diUb/STAMBPL1 complex structure (left) and UbV/STAMBPL1 structure overlaid with diUb (right). The core of STAMBPL1 is shown in green, and the Ins-1 and Ins-2 insertions

Recombinant protein inhibitors for STAMBP deubiquitinases
forms a T-shaped π-stacking interaction with Tyr322 on ins-1 to stabilize the interaction. Meanwhile, the side chain of His73 in UbVSP.1 (equivalent to Leu73 in Ub.wt) forms a hydrogen bond with the hydroxyl group of Tyr367 and is buried in a hydrophobic pocket formed by Tyr367 and Trp345 of STAMBPL1. PISA analysis (37) also reveals that His73 has the largest BSA of 168 Å² among all UbVSP.1 residues (Fig. 2F).

Despite the ins-1 helix being a key region interacting with the distal Ub, it shows a relatively small conformational change compared with the rest of the molecule except for Glu326, a loop residue N-terminal to ins-1. Glu326 has the largest movement of Cα among the whole STAMBPL1JAMM molecule at 4.4 Å (Fig. 2C). This prompted us to look further into the detailed interactions in this region. UbVSP.1 has a glycine at residue 42 (Fig. 2G), and the equivalent site on Ub.wt is occupied by an arginine (Arg42), with its side chain extending toward ins-1, effectively expelling the side chain of Glu326 away from the Ub.wt (Fig. 2H). In UbVSP.1, the R42G mutation creates space to accommodate the side chain of Arg72 in the C-terminal tail from UbVSP.1 (Fig. 2G) to flip toward this vacancy (Fig. 2H). A strong hydrogen bond network is then formed between the Arg72 guanidinium and the backbone carboxyl group of Glu326 in ins-1 and between the amide group of Gln49 of UbVSP.1 with the backbone carbonyl and amide of Val328 and Glu326, thus stabilizing the interaction between the STAMBPL1 and UbVSP.1 (Fig. 2G). In the STAMBPL1/K63-diUb complex, the side chain of Arg72 is oriented toward ins-2 but does not directly contact any STAMBPL1 residues (Fig. 2H). The coordinated mutation of R42G and flip of Arg72 side chain on UbVSP.1 with the movement of Glu326 on STAMBPL1 (Fig. 2, G and H) creates another hotspot for the tight interaction between UbVSP.1 and STAMBPL1.

Table 1
Crystallography data and refinement statistics

| Data collection | Wavelength (Å) | 0.97949 |
|-----------------|---------------|---------|
| Resolution      | 50.00–2.00 (2.03–2.00) | |
| Space group     | C2            | |
| Unit Cell       | a, b, c (Å)   | 63.71, 68.88, 57.33 |
|                 | α, β, γ (°)   | 90.0, 98.5, 90.0 |
| Measured reflections | 70,314     | |
| Unique reflections | 16,078     | |
| l/d             | 16.5 (1.8)   | |
| Rmerge(%)       | 12.3 (7.00)  | |
| CC1/2           | 0.934 (0.769)| |
| Completeness (%)| 99 (96.4)    | |
| Redundancy      | 4.40 (3.40)  | |
| Refinement      | Resolution (Å) | 50.00–2.00 |
|                 | No. Reflections (test set) | 15,388 (690) |
|                 | Rmerge/Rfree (%) | 18.5/21.4 |
|                 | No. Atoms      | |
| Protein         | 1957          | |
| Zinc            | 2             | |
| Water           | 61            | |
| B-factors (Å²)  | 37.8          | |
| Protein         | 40.3          | |
| Zinc            | 40.5          | |
| Water           | 40.5          | |
| RMSD            | Bond lengths (Å) | 0.010 |
|                 | Bond angles (°) | 1.377 |
| Ramachandran plot % residues | 98.8 |
| Favored         | 1.2           | |
| Allowed         | 1.2           | |
| Disallowed      | 0.0           | |

* Values in parentheses are for highest-resolution shell unless otherwise indicated.

three regions: a loop N-terminal to ins-1, the loops around the catalytic site, and the loops chelating the structural zinc ion. A Cα RMSD-based sausage representation of the STAMBPL1 structure visualizes the regions that have the largest conformational change upon UbVSP.1 binding (Fig. 2C).

A comparison of the conformation of the UbVSP.1 and the distal Ub in the STAMBPL1/K63-diUb complex structure when the STAMBPL1JAMM domain of the two structures are aligned reveals a significant conformational difference of the tails of the two bound Ub molecules (residues Arg72 and onward; Fig. 2, D–G). The backbone of the C-terminal tail of UbVSP.1 has the largest conformational movement compared with Ub.wt (Fig. 2D) and is excluded from the catalytic groove and projects in the direction of ins-2 while interacting with ins-1 (Fig. 2E). In contrast, the isopeptide bond of the physiological K63-diUb substrate is, as expected, buried in the catalytic groove and spans the catalytic site in an orientation that is primed for hydrolysis (Fig. 2, E and H). Sequence comparison of UbVSP.1 with Ub.wt (Fig. 1B) and structural analysis (Fig. 2F) suggest that the G75H mutation creates a steric hindrance that prevents the access of the tail to the catalytic groove, thereby providing a structural basis for the observed conformation. Instead, His75 are in blue. It is evident that the UbVSP.1 (magenta) binds to the JAMM domain in the same orientation as that of the distal Ub (yellow), but unlike the distal Ub, the C-terminal tail of UbVSP.1 is excluded from the catalytic groove of STAMBPL1. The side chains of the variant residues H73, H75, and S76 unique to UbVSP.1 are shown in sticks. F, a close-up view of the interactions around the C-terminal tail of UbVSP.1, H73 is buried in an aromatic pocket of STAMBPL1 comprised of Y367 and W345 and the side chain forms a strong hydrogen bond with the hydroxyl group of Y367, and a π-π stacking with W345 of the STAMBPL1. H75 of UbVSP.1 forms a T-shaped π-π stacking through the Cα-H with Y322 of STAMBPL1. The catalytic zinc ion and its coordinating residues are shown in spheres and sticks, respectively. G, a close-up view of the interactions around E326 in STAMBPL1 ins-1. The side chain of Q49 and the guanidinium group of R72 forms a hydrogen bond network with the main chain of E326 and V328 from STAMBPL1. Note: the atoms in the side chain of E326 beyond Cα is not visible in the electron density map. H, for comparison, in the STAMBPL1/K63-diUb structure (PDB:2ZNV), the side chain of R42 (G42 in UbVSP.1) precludes the formation of the hydrogen bond network seen in panel (G), the E326 loop of STAMBPL1, and the R72 of Ub.wt are expelled from forming a tight interaction.
Figure 3. Isothermal titration calorimetry (ITC) measurement of the interaction between Ub, UbVs and STAMBP, STAMBL1. A. Summary table of ITC measurements. N.D. stands for not determined, i.e., cannot be measured due to lack of interaction. B, C. Thermodiagram of ITC measurement of STAMBL1 with UbVs. Specificity index is defined as the quotient of the dissociation constant of a UbV-STAMBL1 complex divided by that of the same UbV in complex with STAMBP. The larger the value, the more specific the UbV is toward STAMBP.
that enhance the binding affinity of the UbVSP.1. To test this hypothesis, we constructed three mutants of Ub.wt, with either a single mutation UbR42G, UbL73H, or a double mutation UbR42G/L73H. These results suggest that however, resulted in a sub-

μ

a single mutation UbR42G,UbL73H, or a double mutation to STAMBPL1, while UbL73H showed only weak binding to STAMBPL1. The double mutant UbR42G/L73H, however, showed a sub-

μ

affinity (K_D of 0.88 μM) only fivefold weaker than that of UbVSP.1, suggesting a synergistic effect of the two mutations. The binding of the mutants with STAMBPL1 show a similar trend; the R42G mutation reduced the binding of the Ub to STAMBPL1 and the L73H mutation only slightly increased the affinity. The double mutant UbR42G/L73H, however, resulted in a sub-

μ

affinity at 0.15 μM, only threefold weaker than the UbVSP.1. These results suggest that the mutations at sites 42 and 73 are the hotspots for UbVSP.1, suggesting a synergistic effect of the two mutations.

To investigate the inhibitory effects of UbVs on STAMPB in vitro, we first performed a fluorescence resonance energy transfer (FRET)-based K63-diUb substrate cleavage assay. We found that UbVSP.1 and UbVSP.3 are potent inhibitors for the isopeptidase activity of STAMBPL1. The half-maximal inhibition (IC_{50}) was 8.4 nM for UbVSP.1 and 9.8 nM for UbVSP.3 both having a Hill slope of ~0.8 (Fig. 4, A and B). To benchmark the inhibitory potency of our UbVs inhibitors, we obtained previously reported STAMPB small-molecule inhibitors having two different chemistries each reported as BC-1471 (33): consisting of a core 2-6-morpholino-4-oxo-3-phenethyl-3,4-dihydroquinazolin-2-yl-thio- and an N-linked tetrahydrofur-an-2-yl-methyl-acetamide (CAS 896683-84-4, racemate) or a furan-2-yl-methyl-acetamide (CAS 896683-78-6). In both cases, we did not observe the inhibitory activity reported for BC-1471 as there was no difference in the diUb deconjugation reaction rate of STAMBPL1 with or without the compounds (Table 2).

Next, we compared the K63-diUb (FRET) cleavage inhibition by the UbVs with STAMBPL1 to the inhibition of full-length STAMBP activated by STAM protein and full-length STAMBL1. STAM contains three Ub-binding domains: VPS27/Hrs/STAM (VHS), Ub-interacting motif (UIM), and SH3 domains. The SH3 domain mediates the interaction of STAM with the SBM motif N-terminal to the JAMM domain of STAMBP. The VHS domain shifts the cleavage preference of STAMBP to longer poly-Ub chains by binding to a Ub that is spatially distant from the JAMM domain and helps position the cleavage site (38), while the UIM domain is proposed to bind to the proximal Ub when the JAMM domain of STAMBP recognizes the distal Ub of diUb (39, 40). As expected from IC_{50} assays, UbVSP.1 resulted in complete inhibition of STAMBPL1 and UbVSP.3 reduced the activity to 10% of the uninhibited enzyme (Table 2, UbV concentration = 1 μM). Full-length STAMBP activated with STAM1 was inhibited by both UbVSP.1 and UbVSP.3, and the activity was reduced to 7% and 13%, respectively. The activity of the paralog STAMBPL1 with the K63-diUb FRET substrate was inhibited to 44% by UbVSP.1; however, there was no observable inhibition by UbVSP.3. This is consistent with the binding affinity data shown in Figure 3.

Next, we assessed the effect of UbVSP.1 and UbVSP.3 using a K63-linkage poly-Ub (Ub2-Ub7) cleavage assay. In this assay, the isopeptidase activity of STAMBP can be visualized by monitoring the appearance of mono-Ub (Ub1) and the disappearance of the Ub2-Ub7 bands (Fig. 5A). STAMBP in complex with different UbV inhibitors was incubated with K63-linkage poly-Ub, and STAMBPL1 samples in the presence and absence of Ub.wt were used as controls. Both UbVSP.1 and UbVSP.3 potently inhibited the isopeptidase activity of STAMBPL1 (Fig. 5B) and full-length STAMBPL1 (Fig. 5C) toward the cleavage of K63-linked poly-Ub chains. In addition, UbVSP.1 appeared to inhibit STAMBPL1 to some extent, whereas UbVSP.3 showed no inhibitory effect with STAMBPL1 (Fig. S2A).

We then compared the inhibitory effects to the small-molecule inhibitor BC-1471 (33), UbVSP.1 exhibited a much greater inhibitory effect to STAMPB than BC-1471 (Fig. 5D). Importantly, the inhibition by UbVSP.1 is dose-dependent, but this is not the case for BC-1471 (Fig. S2B), further confirming that BC-1471 is unlikely a potent inhibitor of STAMBP. In

**UlbvSP.1 and UbvSP.3 are potent STAMPB inhibitors**

To investigate the inhibitory effects of UbVs on STAMPB in vitro, we first performed a fluorescence resonance energy transfer (FRET)-based K63-diUb substrate cleavage assay. We found that UbVSP.1 and UbVSP.3 are potent inhibitors for the isopeptidase activity of STAMBPL1. The half-maximal inhibition (IC_{50}) was 8.4 nM for UbVSP.1 and 9.8 nM for UbVSP.3 both having a Hill slope of ~0.8 (Fig. 4, A and B). To benchmark the inhibitory potency of our UbVs inhibitors, we obtained previously reported STAMPB small-molecule inhibitors having two different chemistries each reported as BC-1471 (33): consisting of a core 2-6-morpholino-4-oxo-3-phenethyl-3,4-dihydroquinazolin-2-yl-thio- and an N-linked tetrahydrofur-an-2-yl-methyl-acetamide (CAS 896683-84-4, racemate) or a furan-2-yl-methyl-acetamide (CAS 896683-78-6). In both cases, we did not observe the inhibitory activity reported for BC-1471 as there was no difference in the diUb deconjugation reaction rate of STAMBPL1 with or without the compounds (Table 2).

Next, we compared the K63-diUb (FRET) cleavage inhibition by the UbVs with STAMBPL1 to the inhibition of full-length STAMBP activated by STAM protein and full-length STAMBL1. STAM contains three Ub-binding domains: VPS27/Hrs/STAM (VHS), Ub-interacting motif (UIM), and SH3 domains. The SH3 domain mediates the interaction of STAM with the SBM motif N-terminal to the JAMM domain of STAMBP. The VHS domain shifts the cleavage preference of STAMBP to longer poly-Ub chains by binding to a Ub that is spatially distant from the JAMM domain and helps position the cleavage site (38), while the UIM domain is proposed to bind to the proximal Ub when the JAMM domain of STAMBP recognizes the distal Ub of diUb (39, 40). As expected from IC_{50} assays, UbVSP.1 resulted in complete inhibition of STAMBPL1 and UbVSP.3 reduced the activity to 10% of the uninhibited enzyme (Table 2, UbV concentration = 1 μM). Full-length STAMBP activated with STAM1 was inhibited by both UbVSP.1 and UbVSP.3, and the activity was reduced to 7% and 13%, respectively. The activity of the paralog STAMBPL1 with the K63-diUb FRET substrate was inhibited to 44% by UbVSP.1; however, there was no observable inhibition by UbVSP.3. This is consistent with the binding affinity data shown in Figure 3.

Next, we assessed the effect of UbVSP.1 and UbVSP.3 using a K63-linkage poly-Ub (Ub2-Ub7) cleavage assay. In this assay, the isopeptidase activity of STAMBP can be visualized by monitoring the appearance of mono-Ub (Ub1) and the disappearance of the Ub2-Ub7 bands (Fig. 5A). STAMBP in complex with different UbV inhibitors was incubated with K63-linkage poly-Ub, and STAMBPL1 samples in the presence and absence of Ub.wt were used as controls. Both UbVSP.1 and UbVSP.3 potently inhibited the isopeptidase activity of STAMBPL1 (Fig. 5B) and full-length STAMBPL1 (Fig. 5C) toward the cleavage of K63-linked poly-Ub chains. In addition, UbVSP.1 appeared to inhibit STAMBPL1 to some extent, whereas UbVSP.3 showed no inhibitory effect with STAMBPL1 (Fig. S2A).

We then compared the inhibitory effects to the small-molecule inhibitor BC-1471 (33), UbVSP.1 exhibited a much greater inhibitory effect to STAMPB than BC-1471 (Fig. 5D). Importantly, the inhibition by UbVSP.1 is dose-dependent, but this is not the case for BC-1471 (Fig. S2B), further confirming that BC-1471 is unlikely a potent inhibitor of STAMBP. In

---

**Figure 4. UbV inhibition of STAMBPL1 diUb isopeptidase activity.** Inhibition of STAMBPL1 isopeptidase activity by (A) UbVSP.1 and (B) UbVSP.3 shown as dose–response curves using a K63-linked diUb FRET substrate. The IC_{50} value was determined as the concentration of UbV that inhibited 50% of proteolytic activity. Curves were fit by nonlinear regression using the formula for inhibitor concentration versus normalized response (variable slope) in GraphPad Prism 8. A Hill slope of ~0.8 was calculated for both inhibitors representing a single-site binding model.
addition, we observed inhibition of STAM1-activated full-length STAMBP by both UbVSP.1 and UbVSP.3 in this chain cleavage assay (Fig. S2C). Finally, neither UbVSP.1 nor UbVSP.3 showed inhibitory effects to other JAMM DUBs, such as BRISC (Fig. S2D) and MYSM1 (Fig. S2E), which indicated the inhibitory specificity of UbVSP.1 and UbVSP.3.

Table 2

| Enzyme                          | Activity with 1 μM inhibitor (% of uninhibited activity)a |
|---------------------------------|----------------------------------------------------------|
| STAMBP/STAM1+UbVSP.1            | 7.2 ± 0.6                                                |
| STAMBP/STAM1+UbVSP.3            | 13.4 ± 0.2                                               |
| STAMBP1+UbVSP.1                 | 44 ± 3                                                   |
| STAMBP1+UbVSP.3                 | 118 ± 5                                                  |
| STAMBP2+UbVSP.1                 | 0                                                        |
| STAMBP2+UbVSP.3                 | 11 ± 2                                                   |
| STAMBP3MAMM+UbVSP.3             | 107 ± 2                                                  |
| STAMBP3MAMM+BC-1471 (CAS 896683-84-4) | 96 ± 3                             |

a Reactions were measured in triplicate at room temperature with 5 nM enzyme and 100 nM diUb K63 TAMRA substrate. Reported activity is normalized to identical reactions without added inhibitor.

Discussion

Over the past few years, the phage-display-based protein engineering platform targeting Ub-mediated protein–protein interactions (34) has been utilized to develop potent and specific modulators for a repertoire of UPS components, including E2 conjugating enzymes (41), E3 ligases (42–44), and DUBs (36, 45–47). These DUBs include seven USPs (USP2, USP7, USP8, USP10, USP15, USP21, and USP37); one OTU (OTUB1); and two viral papain-like proteases (MERS-CoV PLpro and CCHFV-L, which have USP and OTU structural fold, respectively) (34, 36, 45–47).

The UbVs described herein for STAMBP and STAMBPL1 are the first examples of protein-based potent and specific deubiquitination inhibitor developed for the JAMM family DUBs. Previously, a moderately selective (>5-fold toward several JAMM DUBs) RPN11 inhibitor capzimin was generated by optimization of a nonspecific small-molecule inhibitor 8-TQ, which has structural similarity with chelating agent 8-hydroxyquinoline (25). Moreover, a small-molecule inhibitor CSN5i-3 was developed to inhibit CSN5, demonstrating the feasibility of targeted inhibition of JAMM DUBs (26). CSN5 is...
unique in that it needs the whole CSN complex to elicit de neddylation activity and has NEDD8-conjugated cullin-RING E3 ligases as specific substrates. While BC-1471 was recently reported as a STAMBP chemical inhibitor (33), we were not able to detect its inhibitory activity in our in vitro assay. We note that BC-1471 was identified from an in silico screening method with no confirmation using a cocystal structure or an orthogonal biophysical technique to validate a direct binding (33). In addition, previous in vitro assays did not show complete inhibition of STAMBP activity by BC-1471 at high concentrations (100 μM) or under a native cellular phenotype such that the observed inhibition could be the result of off-target effects (33).

Similar to other UbVs targeting USPs, including UbVcore for USP37, UbV7.2 for USP7, and UbV10.1 for USP10 (36, 45), UbVSP.1 has enhanced affinity primarily due to amino-acid substitutions at the C-terminal variable region (N60–G76+). Structural characterization of the STAMBP1:UbVSP.1 complex, along with mutation analysis of amino-acid substitutions, identified hotspot residues contributing to the enhanced affinity of the variants for the catalytic domains of STAMBP and STAMBP1. With a single residue substitution (L73H) in the C-terminus alone, the affinity of Ub.wt for STAMBP was enhanced nearly sevenfold. Subsequently, a double mutation (R42G, L73H) resulting lack of inhibition of STAMBPL1 activity may be explained by the difference in the interaction with these residues. The preservation of Arg42 in UbVSP.3 prevents its Arg72 from flipping toward ins-1 and participating in the hydrogen bond network as observed in the STAMBPL1:UbVSP.1 structure. In contrast, the side chain of Gln316 of STAMPB could form water-bridged hydrogen bonds with Arg42 and Arg72, thereby resulting in a reorganization of the ins-1 loop. Although no structure of human STAMBP in complex with Ub.wt has been reported, such a water-bridged interaction was observed in the complex structure of the yeast STAMBP orthologue Sst2 in complex with K63-diUb (PDB:4NQL, Fig. S3B). The increased affinity of UbVSP.3 for STAMBP over Ub.wt is partially explained by the same L73H substitution in UbVSP.1 (as demonstrated from the observed sevenfold increase in affinity from ITC experiments). Additional affinity could be caused by additional hydrophobic interactions of the introduced R74F mutation with residues Tyr310, Phe395, and Val347 (Tyr322, Phe407, and Val359 STAMBP1 numbering). The five residues of UbVSP.3 tail (Phe74–Met78) differ significantly from those in UbVSP.1 (Fig. 1A) and may form additional enzyme-specific interactions divergent from those observed for the respective residues in the STAMBP1:UbVSP.1 structure. While a relative specificity is observed for UbVSP.1 and UbVSP.3 against other DUBs, a thorough proteomics analysis may be required before using these molecules in target validation experiments. For example, there are more than 20 different Ub-binding domains (UBDs) identified to date, and they are quite diverse at the structure level (50).

We noted that STAMBP UbVs do not have the key mutation position 10 (i.e., G10A/V mutation that can lead to UbV dimerization) necessary to increase affinity for binding to Ub-interacting motifs (UIMs) (45, 51, 52). However, UbVSP.1 and
Recombinant protein inhibitors for STAMBP deubiquitinases

UbV<sup>SP.3</sup> may potentially interfere with certain Ub-UBD interactions. Like the off-target effects in drug discovery, whether UbV<sup>SP.1</sup> or UbV<sup>SP.3</sup> may bind to other proteins, including those that do not contain UBDs, should be tested in separate cellular experiments.

Given the success of generating first-in-class Ub inhibitors for STAMBP and STAMBPL1, further development of UbV modulators is conceivable for the remaining 13 members of the JAMM family, including the seven pseudo-DUBs. While the structural elements of the JAMM domain persist, many of the residues composing the canonical Ub binding site are divergent. Employing UbV selection strategies opens the opportunity of utilizing the deviation from the canonical binding site as a unique target for protein–protein interactions. Of particular interest are the BRCC36-ABRAXAS or -KIAA0157 complexes in the BRCA1-A and BRISC holocomplexes, respectively (53). The aforementioned heterodimers with BRCC36 form the catalytic cores of their respective holocomplexes, incorporating a dimer of JAMM and pseudo-JAMM domains. Targeting these structures with UbVs would provide a more rapid and specific option than conducting small-molecule inhibitor screens. Finally, the recombinant UbV modulators of the pseudo-DUBs will be ideal probes for evaluating the biological functions of these pseudo-enzymes without ablating their potential roles as molecular scaffolds in cellular processes.

Experimental procedures

**Protein overexpression and purification**

All constructs for structural biology and ITC binding measurement were cloned into a pET28-MHL vector, which encodes a TEV protease cleavable N-terminal His<sub>6</sub>-tag that will leave a nonnative glycine residue after TEV treatment of the target protein, and overexpressed in E. coli strain BL21 (DE3) with 250 μM isopropyl-β-D-thiogalactopyranoside (IPTG) induction using a protocol described previously (54). 1× PBS with 5% glycerol was used as the base buffer for the whole purification process with added supplements in different purification steps. Briefly, cell pellets from 2 l culture were used for each construct. The sonication disrupted cells were first clarified with centrifugation and purified using open column Ni-NTA chromatography. The bound proteins were washed with the base buffer supplemented with 20 mM imidazole and eluted with the buffer containing 250 mM imidazole. The eluates were pooled and digested with TEV protease at 30:1 (w/w) protein:TEV, then dialyzed overnight against 1× PBS. The dialyzed solution was passed through 5 ml Ni-NTA resins again to remove uncut proteins and TEV protease. The flow-through was further purified by cation-exchange chromatography on a 5 ml HiTrap S column (GE Healthcare) with a salt gradient of 0 to 1 M NaCl in 1× PBS supplemented with 1 mM DTT. The fractions containing the target proteins were collected and loaded on a Superdex 200 size-exclusion chromatography (SEC) column. The eluates were then collected, pooled, and concentrated by centrifugal filters (Amicon mwco. 10 kDa) to a final concentration of 10 to 20 mg/ml. The final purities of the proteins were about 99%, judging from SDS-PAGE and Coomassie Brilliant Blue (CBB) staining. The removal of the His<sub>6</sub> tag of the proteins was confirmed using mass spectroscopy.

Three constructs corresponding to the full-length (residues 1–424) and JAMM domain (residues 219–424) of STAMBP in reference to NP_998787.1 and the JAMM domain (residues 263–436) of STAMBPL1 in reference to NP_065850.1 were used for UbV selection. The constructs were cloned into a modified pET-28a vector encoding a TEV cleavable N-terminal avi-tag for <em>in vivo</em> biotinylation and a C-terminal His<sub>6</sub> tag and transformed into a BL21 (DE3) E. coli strain harboring a plasmid containing the BirA ligase. The proteins were purified using Ni-NTA chromatography followed by SEC before being used for UbV selection. The purities of the preparations are higher than 95% based on SDS-PAGE and CBB staining.

**Crystallization of the protein complex**

Different combinations of UbVs in complex with STAMBP<sup>JAMM</sup> or STAMBPL1<sup>JAMM</sup> were prepared for crystallization trials. The corresponding pairs of two proteins were mixed at 1:1.1 molarity ratio (DUB:UbV) and loaded on a Superdex 200 SEC column. The fractions corresponding to the protein complex were pooled and concentrated by centrifugal filters (Amicon mwco. 30 kDa) to a final concentration of 16 mg/ml. Crystallization trials were set using 0.5 μl protein solution plus 0.5 μl reservoir solution in a sitting drop vaporization setup. Three crystal screening kits were tried for each sample: SGC-II, Red Wings, and Hampton Research Protein Complex. Multiple crystal forms were obtained, but only certain conditions gave a crystal containing both poly-peptides. For all the combinations of the DUB:UbV complexes tried, we were only able to obtain a crystal of the STAMBPL1<sup>JAMM</sup>/UbV<sup>SP.1</sup> complex. The crystal used for data collection was optimized using hanging drop vaporization set up in a reservoir solution containing 20% PEG1500, 0.2 M NaCl, 0.1 M HEPES, pH 7.5. The crystal was transferred to a cryoprotectant containing 15% ethylene glycol in the reservoir solution before flash-freezing in liquid nitrogen.

**Diffraction data collection and structural determination**

X-ray diffraction data for structure determination were collected at the Canadian Light Source Inc (CLSI) beamline 08ID-1 (CMCF-ID) (55). The dataset was processed with the HKL-3000 suite (56). The structures were solved by molecular replacement using PHASER v.2.6.1 using PDBs 2ZNR and 1UBQ as the search template for STAMBPL1 and UbV<sup>SP.1</sup>, respectively. COOT was used for model building and visualization, REFMAC (v.5.8.0135) for restrained refinement. The final model was validated by MOLPROBITY. All molecular graphics were prepared with PyMOL v.2.4.0 (Schrödinger, Inc)

**ITC measurement**

For ITC measurement, proteins were dialyzed overnight with PBS buffer containing 1 mM TCEP and adjusted to a final concentration of 50 μM. All ITC measurements were
Recombinant protein inhibitors for STAMBP deubiquitinas

performed at 25 °C on a NanoITC (TA Instruments). A total of 25 injections, each of 5 μl Ub.wt, mutants, or UbVs were delivered into a sample cell of 200 μl containing one of the STAMBPJAMM or STAMBP1JAMM. The data were analyzed using the NanoAnalyzer software supplied by the manufacturer and fitted to a one-site binding model.

Phage display selections and ELISA to evaluate binding

The phage-displayed UbV library used for selection was reapplied from Library 2 as previously described (34). Protein immobilization and the following phage selections were done according to standard protocols (57). Briefly, purified STAMBP proteins (full-length or JAMM domain) were coated on 96-well MaxiSorp plates by adding 100 μl of 1 μM proteins and incubating overnight at 4 °C. Five rounds of phage display selections were performed as follows: a) Preparation of the phage library pool, within which each phage particle displays a unique UbV and encapsulates the UbV encoding DNA in a phagemid; b) The pool of phage-displayed UbV library is applied to immobilized STAMBP; c) STAMBP-binding phage is captured, and nonbinding phage is washed away; d) Bound phage is amplified by infection of bacterial host E. coli (OmniMAX); e) Individual phage with improved binding properties obtained from round 4 and round 5 is identified by phage ELISA (see below) and subjected to DNA sequencing of the phagemids to obtain UbV sequences (43). High-affinity UbVs identified from phage ELISA were cloned into expression vectors, including a FLAG-tag epitope, expressed in E. coli, and purified. For the ELISA experiments, proteins were immobilized on 384-well MaxiSorp plates (Thermo Scientific 12665347) by adding 30 μl of 1 μM protein solution for overnight incubation at 4 °C. Phage and protein ELISAs with immobilized proteins were performed as described before. Binding of phage or FLAG-tagged UbVs was detected using anti-M13-HRP (GE Healthcare 27942101) or anti-FLAG-HRP antibody (Sigma-Aldrich A8592), respectively. To measure the half-maximal effective binding concentration (EC₅₀) of the UbVs' binding to the immobilized DUB, the concentration of UbVs in solution was varied from 0 to 4 μM by twofold serial dilutions. EC₅₀ values were calculated using the GraphPad Prism (version 5.0a) software with the built-in equation (nonlinear regression curve).

Inhibition of STAMBPJAMM diUb isopeptidase activity by UbVs

Inhibition concentrations were determined using a FRET-based diUb cleavage reaction to measure isopeptide hydrolysis by the STAMBPJAMM domain. Fluorescence of hydrolyzed K63-linked diUb (TAMRA/QXL position 3 labeled, Boston Biochem #UCB-330) was measured on a BioTek synergy LX plate reader equipped with a red filter cube assembly (ex. 530 nm, em. 590 nm) for 60 min at ambient temperature (22 °C). Enzyme (2 nM) and UbVs were preincubated for 10 min at ambient temperature before addition of the diUb substrate (100 nM) in 50 μl reaction buffer (50 mM HEPES pH7.5, 100 mM NaCl, 0.01% v/v Tween 20, 0.01 mg/ml BSA, 5 mM DTT). Reactions were replicated in triplicate (N = 3) for varying concentrations of UbV (1 μM–0.1 nM). The rate of reaction was determined from the slope of the initial linear phase of the reaction. Reaction rates were averaged and normalized to the negative control (no inhibitor) then plotted against UbV concentrations in GraphPad Prism 8. In total, 50% inhibition concentrations were determined by nonlinear regression using the formula for inhibitor concentration versus normalized response (variable slope).

Comparison of diUb isopeptidase inhibition with full-length STAMBP and STAMBP1

To compare the inhibition of STAMBPJAMM by UbVSP.1 and UbVSP.3 with wild-type enzymes, inhibition was evaluated with full-length STAMBP (Boston Biochem #E-549) (activated with STAM1 (Boston Biochem #E-550)) and STAMBP1 (Boston Biochem #E-551). Reactions were measured with similar conditions as were used for measuring STAMBPJAMM inhibition. Each reaction instead had 1 μM of UbV and 5 nM of enzyme with 100 nM diUb (K63). STAMBP was preincubated with STAM1 (final concentration of 100 nM) for 10 min prior to the addition of UbV (final concentration of 1 μM). The BC-1471 compounds (TargetMol, CAS 896683-84-4 and CAS 896683-78-6) were also evaluated with STAMBPJAMM under identical conditions with a final concentration of 1 μM. Initial reaction rates were measured from the slope of the linear portion of the reaction. Reactions were measured in triplicate (N = 3) and averaged to determine the inhibited reaction rates. Inhibited reaction rates were normalized to control reactions for each enzyme without inhibitor.

Inhibition assay with poly-Ub cleavage

Inhibition assays were conducted with biotinylated K63-linked poly-Ub chains, a mixture of poly-Ub chains (Ub2–Ub7) (Boston Biochem #UCB-330-050), as the substrate. Assays were performed in a buffer [50 mM HEPES (pH 8.0), 150 mM NaCl, 1 mM TCEP] containing 0.2 μM substrate, DUB (in sub-μM range with some variations), and Ub.wt. (in same concentration as UbVs), UbVs (UbV:DUB = 5:1 for STAMBP and STAMBPJAMM, 20:1 for STAMBP1, 10:1 for BRISC and MYSM1), STAM1 (STAM1:DUB = 5:1) or BC-1471 (TargetMol) at indicated concentrations. Ub.wt, UbVs, and BC-1471 were incubated with DUB at room temperature for 5 min before adding the poly-Ub substrates, and STAM1 was added and preincubated with DUB before adding UbVs/Ub.wt. Reaction mixtures were incubated at 37 °C for indicated reaction times and stopped by adding 1 mM EDTA and SDS-PAGE loading buffer. Samples were resolved by tricine-SDS-PAGE and visualized by Western blots probed by Ub-antibody Extravadin-Peroxidase (Sigma #E2886). All experiments were conducted in triplicate (N = 3).

Data availability

The atomic coordinates and structure factors (Code:7L97) have been deposited in the Protein Data Bank (https://wwpdb.org). PyMOL script for generating the sausage view is
Recombinant protein inhibitors for STAMBP deubiquitinases

upload to GitHub at https://github.com/tongalumina/rmsdca. All other data are included in this manuscript.

Supporting information—This article contains supporting information.

Acknowledgments—We greatly appreciate help from Dr. Sachdev S. Sidhu (University of Toronto), who provided the UbV library. We sincerely thank Dr. Elton Zeqiraj (University of Leeds) for providing BRISC complex proteins. The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUBOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Pfizer and Takeda.

Author contributions—Q. L., E. M., Y. T., and W. Z. conceptualization; Y. G., Q. L., E. M., C. C., F. H., J. F., G. L., A. D., Q. Z., and Y. T. data curation; Y. G., Q. L., E. M., C. C., F. H., J. F., G. L., A. D., Q. Z., and Y. T. formal analysis; Y. T. and W. Z. funding acquisition; Y. G., Q. L., E. M., C. C., F. H., J. F., A. D., Q. Z., H. Z., and W. Z. investigation; Y. G., Q. L., E. M., C. C., F. H., J. F., A. D., Q. Z., H. Z., and W. Z. methodology; E. M., Y. T., and W. Z. project administration; H. Z. and W. Z. resources; Y. T. and W. Z. supervision; Y. G. and E. M. validation; Q. L., E. M., Y. T., and W. Z. writing—original draft; Q. L., E. M., C. C., Y. T., and W. Z. writing—review and editing.

Funding and additional information—This research was funded by NSERC Discovery Grants awarded to W. Z. (RGPIN-2019-05721) and Y. T. (RGPIN-2017-06520). Y. G. is a visiting scholar sponsored by the Excellent Young Teachers program and Innovation Fund of Guangdong Ocean University, China. Q. L. is supported by an OGS scholarship. E. M. was a MITACS Industrial Postdoctoral Fellow with funding provided by Mitacs and ProteinQure Inc. W. Z. is currently a CIFAR Azrieli Global Scholar in the Humans & The Microbiome Program. W. Z. is also a recipient of the Cancer Research Society/BMO Bank of Montreal Scholarship for the Next Generation of Scientists.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: BRCC36, BRCA1/BRCA2 containing complex subunit 36; CSN5, COP9 signalosome subunit 5; DUB, deubiquitinases; JAMM, JAB1/MPN/MOV34; MIT, microtubule interacting and trafficking; MID, Machado-Josephin domain; OTU, ovarian tumor protease; SMB, SH3-binding motif; STAMBP, STAM-binding protein; Ub, ubiquitin; UbV, Ub variant; UCH, ubiquitin C-terminal hydrolase; UPS, Ub-proteasome system; USP, Ub-specific protease; ZUP, zinc finger containing ubiquitin peptidase.

References
1. Hu, H. and Sun, S. C. (2016) Ubiquitin signaling in immune responses. Cell Res. 26, 457–483
2. Huang, T. T., and D’Andrea, A. D. (2006) Regulation of DNA repair by ubiquitylation. Nat. Rev. Mol. Cell Biol. 7, 323–334
3. Nakayama, K. I., and Nakayama, K. (2006) Ubiquitin ligases: Cell-cycle control and cancer. Nat. Rev. Cancer 6, 369–381
4. Swatek, K. N., and Komander, D. (2016) Ubiquitin modifications. Cell Res. 26, 399–422
5. Chen, Z. J., and Sun, L. J. (2009) Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275–286
6. Harrigan, J. A., Jiacq, X., Martin, N. M., and Jackson, S. P. (2018) Deubiquitinating enzyme-mediated drug discovery: Emerging opportunities. Nat. Rev. Drug Discov. 17, 57–77
7. Lill, J. R., and Wertz, I. E. (2014) Toward understanding ubiquitin-modifying enzymes: From pharmacological targeting to proteomics. Trends Pharmacol. Sci. 35, 187–207
8. Abdul Rehman, S. A., Kristariyanto, Y. A., Choi, S. Y., Nkosi, P. I., Weidlich, S., Labib, K., Hofmann, K., and Kulathu, Y. (2016) MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol. Cell 63, 146–155
9. Coleman, K. E., and Huang, T. T. (2018) In a class of its own: A new family of deubiquitinases promotes genome stability. Mol. Cell 70, 1–3
10. Kemp, M. (2016) Recent advances in the discovery of deubiquitinating enzyme inhibitors. Prog. Med. Chem. 55, 149–192
11. Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., Buser-Doepner, C., Campbell, R. M., Carter, A. J., Cohen, P., Copeland, R. A., et al. (2015) The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536–541
12. Zhang, W., and Sidhu, S. S. (2018) Drug development: Allosteric inhibitors hit USP7 ‘hard’. Nat. Chem. Biol. 14, 110–111
13. Colland, F., Formstecher, E., Jaque, X., Reverdy, C., Planquette, C., Conrath, S., Trouplin, V., Bianchi, J., Asushev, V. N., Camonis, J., Calabrese, A., Borg-Capra, C., Sippel, W., Collura, V., Boissy, G., et al. (2009) Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 8, 2286–2295
14. Gavory, G., O’Dowd, C. R., Helm, M. D., Flax, J., Arkoudis, E., Dossang, A., Hughes, C., Cassidy, E., McClelland, K., Odrzywol, E., Page, N., Barker, O., Miel, H., and Harrison, T. (2018) Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat. Chem. Biol. 14, 118–125
15. Turnbull, A. P., Ioannisidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C., Tonkin, L. M., Townsend, E. C., Bucer, S. M., Lancia, D. R., Caravella, I. A., Toms, A. V., Charlton, T. M., Lahdenranta, J., Wilker, E., et al. (2017) Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature 550, 481–486
16. Katgeaya, L., Di Lello, P., Rougé, L., Pastor, R., Clark, K. R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J. P., Prakash, S., Heideker, J., McClelland, M., Ritorto, M. S., Alessi, D. R., Trost, M., et al. (2017) USP7 small-molecule inhibitors interfere with ubiquitin binding. Nature 550, 534–538
17. Clague, M. J., and Urbé, S. (2006) Endocytosis: The DUB version. Trends Cell Biol. 16, 551–559
18. Shrestha, R. K., Ronau, J. A., Davies, C. W., Guenette, R. G., Strierer, E. R., Paul, L. N., and Das, C. (2014) Insights into the mechanism of deubiquitination by JAMM-VARGAS ubiquitinases from cocystal structures of the enzyme with the substrate and product. Biochemistry 53, 3199–3217
19. Nijman, S. M. B., Luna-Vargas, M. A. P., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., and Bernards, R. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773–786
20. Zhu, P., Zhou, W., Wang, J., Puc, J., Ohgi, K. A., Erdjument-Bromage, H., Tempst, P., Glass, C. K., and Rosenfeld, M. G. (2007) A histone H2A deubiquitinase complex coordinating histone acetylation and H1 disassociation in transcriptional regulation. Mol. Cell 27, 609–621
21. Zeqiraj, E., Tian, L., Piggott, C. A., Pillon, M. C., Duffy, N. M., Cecarelli, D. F., Keszei, A. F. A., Lorenzen, K., Kurinov, I., Orlicky, S., Gish, G. D., Heck, A. J. R., Guarné, Á., Greenberg, R. A., and Sichler, F. (2015) Higher-order assembly of BRCC36-KIAA0157 is required for DUB activity and biological function. Mol. Cell 59, 970–983
22. Kweon, S. M., Chen, Y., Moon, E., Kvederaviciute, K., Klimasauskas, S., and Feldman, D. E. (2019) An adversarial DNA N6-methyladenine-sensor network preserves polycomb silencing. Mol. Cell 74, 1138–1147.e6
23. Cooper, E. M., Cutcliffe, C., Kristianen, T. Z., Pandey, A., Pickart, C. M., and Cohen, R. E. (2009) K63-specific deubiquitination by two JAMM/MPN+ complexes: BRISC-associated Brec36 and proteasomal Pohl. EMBO J. 28, 621–631
Recombinant protein inhibitors for STAMBP deubiquinases

24. Lauinger, L., Li, J., Shostak, A., Cemel, I. A., Ha, N., Zhang, Y., Merkl, P. E., Oehmeyer, S., Stankovic-Valentin, N., Schaefteier, T., Wever, W. J., Bowers, A. A., Carter, K. P., Palmer, A. E., Tschochner, H., et al. (2017) Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metallocistrapases. *Nat. Chem. Biol.* 13, 709–714

25. Li, J., Yakushi, T., Parlati, F., MacKinnon, A. L., Perez, C., Ma, Y., Carter, K. P., Colaco, Y., Magnuson, G., Brown, B., Nguyen, K., Vasile, S., Suyama, E., Smith, L. H., Sergienko, E., et al. (2017) Capzipmin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. *Nat. Chem. Biol.* 13, 486–493

26. Schlierf, A., Altmann, E., Quancard, J., Jefferson, A. B., Assenberg, R., Schwerdtfeger, C., Brasher, B. B., Csececelleri, D. F. J., Moffat, J., Sicheri, F., and Marschall, R. J. (1996) System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes. *Cell 62*, 121–136

27. Greblik, M., Orlicky, S., Sartori, M. A., Tang, X., Marcon, E., Kurinov, I., Greenblatt, J. F., Tyers, M., Moffat, J., Sicheri, F., and Sidhu, S. S. (2016) Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cull binding site on the Skp1-F-box interface. *Proc. Natl. Acad. Sci. U. S. A.* 113, 3527–3532

28. Manczyk, N., Veggianni, G., Teyra, J., Strichau, A. W., Sidhu, S. S., and Sicheri, F. (2019) The ubiquitin interacting motifs of USP37 act on the proximal Ub of a di-Ub chain to enhance catalytic efficiency. *Sci. Rep.* 9, 1–11

29. Teyra, J., Singer, A. U., Schmitges, F. W., Jaynes, P., Kit Leng Lui, S., Polyak, M. J., Fodil, N., Krieger, J. R., Tong, J., Schwerdtfeger, C., Brasher, B. B., Csececelleri, D. F. J., Moffat, J., Sicheri, F., Moran, M. F., et al. (2019) Structural and functional characterization of ubiquitin variant inhibitors of USP15. *Structures* 7, 590–605.e5

30. Zhang, W., Bailey-Elkin, B. A., Knaap, R. C. M., Khare, B., Dalebout, T. J., Johnson, G. G., van Kasteren, P. B., Leich, N. J., Gu, J., He, W., Kikkert, M., Mark, B. L., and Sidhu, S. S. (2017) Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants. *PLOS Pathog.* 13, e1006372

31. Mund, T., Lewis, M. J., Maslen, S., and Pelham, H. R. (2014) Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. *Proc. Natl. Acad. Sci. U. S. A.* 111, 16736–16741

32. Korelic, M., Manczyk, N., Pawlenko, A., Kurinov, I., Sidhu, S. S., and Sicheri, F. (2018) A structure-based strategy for engineering selective ubiquitin variant inhibitors of Skp1-Cull-F-box ubiquitin ligases. *Structure* 26, 1226–1236.e3

33. Dikic, I., Nakatsuki, S., and Walters, K. I. (2009) Ubiquitin-binding domains from structures to functions. *Nat. Rev. Mol. Cell Biol.* 10, 659–671

34. Manczyk, N., Yates, B. P., Veggianni, G., Ernst, A., Sicheri, F., and Sidhu, S. S. (2017) Structural and functional characterization of a ubiquitin variant engineered for tight and specific binding to an alpha-helical ubiquitin interacting motif. *Protein Sci.* 26, 1060–1069

35. Manczyk, N., Veggianni, G., Gish, G. D., Yates, B. P., Ernst, A., Sidhu, S. S., and Sicheri, F. (2019) Dimerization of a ubiquitin variant leads to high affinity interactions with a ubiquitin interacting motif. *Protein Sci.* 28, 848–856

36. Walden, M., Tian, L., Ross, R. L., Sykora, U. M., Byrne, D. P., Hesketh, E. L., Masandi, S. K., Cassel, J., George, R., Ault, J. R., El Oualid, F., Pawlowski, K., Salvino, J. M., Eyers, P. A., Ranson, N. A., et al. (2019) Metabolic control of BRISC-SHMT2 assembly regulates immune signalling. *Nature* 570, 194–199

37. Paudel, P., Zhang, Q., Leung, C., Greenberg, H. C., Guo, Y., Chern, Y. H., Dong, A., Li, Y., Vedadi, M., Zhuang, Z., and Tong, Y. (2019) Crystal structure and activity-based labeling reveal the mechanisms for linkage-specific substrate recognition by deubiquitinas USP9X. *Proc. Natl. Acad. Sci. U. S. A.* 116, 7288–7297

38. Grochulski, P., Fodje, M. N., Gorin, J., Labiuk, S. L., and Berg, R. (2011) Beamline 08ID-1, the prime beamline of the Canadian macromolecular crystallography facility. *J. Synchrotron Radiat.* 18, 681–684

39. Minor, W., Cymborowski, M., Otwinowski, Z., and Chruszcz, M. (2006) HKL-3000: The integration of data reduction and structure solution from diffraction images to an initial model in minutes. *Acta Crystalllogr. D Biol. Crystallogr.* 62, 859–866

40. Tomkian, R., Zhang, Y., Boone, C., and Sidhu, S. S. (2007) Identifying specificity profiles for peptide recognition modules from phase-display peptide libraries. *Nat. Protoc.* 2, 1366–1386